Vivozon Registers Patent for Non-Narcotic Analgesic 'VVZ-2471' in South Korea and Israel
The oral non-narcotic analgesic 'VVZ-2471', currently under development by the domestic pharmaceutical company Vivozon, has been granted patents in South Korea and Israel. This patent registration is highly significant as it marks international recognition of the new drug's technological capabilities.
'VVZ-2471', developed by Vivozon, aims to provide powerful pain relief while reducing the side effects associated with narcotic analgesics. As existing narcotic painkillers raise concerns regarding side effects such as addiction, there is high anticipation for new therapeutic agents that can serve as alternatives.
This patent protects the rights to the drug's composition and manufacturing methods, and is expected to serve as an important stepping stone for entering the global market. Through the acquisition of this patent, Vivozon plans to further strengthen its competitiveness in overseas markets.
Moving forward, Vivozon intends to accelerate the development of the new drug by proceeding with clinical trials without setbacks. As the demand for non-narcotic analgesics is steadily increasing worldwide, the positive impact this achievement will have on the domestic pharmaceutical industry is drawing attention.